Skip to main content
SpringerLink
Log in

Parenteral Direct Antithrombins

  • Chapter
Antithrombotics

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 132))

  • 165 Accesses

Abstract

The development of thrombosis within a diseased artery or vein is responsible for acute coronary syndromes, deep venous thrombosis, pulmonary embolism, cerebral vascular accidents, and limb and bowel ischemia. Thrombin plays a central role in the process of thrombosis. Heparin, which is currently the mainstay of antithrombotic therapy for the acute phase of all of these clinical syndromes, is only partially effective. The limitations of heparin therapy may be linked to several features of its mode of action, which may be overcome by the use of direct thrombin inhibitors, a new class of agents that specifically and potently antagonize the actions of thrombin.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Agnelli G, Pascucci C, Cosmi B, Nenci GG (1990) The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits. Thrombosis Haemost 63:204–207

    CAS  Google Scholar 

  • Antman EM (1994) Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin

    Google Scholar 

  • Antman EM (1996) Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 94: 911–921

    PubMed  CAS  Google Scholar 

  • Bichler J, Baynes JW, Thorpe SR (1993) Catabolism of hirudin and thrombin-hirudin complexes in the rat. Biochemistry 296:771–776

    CAS  Google Scholar 

  • Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J et al (1995) Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 333:764–769

    CAS  Google Scholar 

  • Buchwald AB, Sandrock D, Unterberg C, Ebbecke M, Nebendahl K, Luders S et al (1993) Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin. J Am Coll Cardiol 21:249–254

    Article  PubMed  CAS  Google Scholar 

  • Callas DD, Hoppensteadt D, Fareed J (1995) Comparative studies on the anticoagulant and protease generation inhibitory actions of newly developed site-directed thrombin inhibitory drugs. Efegatran, argatroban, hirulog, and hirudin. Semin Thromb Hemost 21:177–183

    Article  CAS  Google Scholar 

  • Cannon CP, Braunwald E (1995) Hirudin: initial results in acute myocardial infarction, unstable angina and angioplasty. J Am Coll Cardiol 25 [Suppl 7]:30S–37S

    Article  PubMed  CAS  Google Scholar 

  • Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS et al (1994) A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 23:993–1003

    Article  PubMed  CAS  Google Scholar 

  • Chao FC, Tullis JL, Kenney DM, Conneely GS, Doyle JR (1974) Concentration effects of platelets, fibrinogen and thrombin on platelet aggregation and fibrin clotting. Thromb Diath Haemorrh 32:216–231

    PubMed  CAS  Google Scholar 

  • Doutremepuich C, Deharo E, Guyot M, Lalanne MC, Walenga J, Fareed J (1989) Antithrombotic activity of recombinant hirudin in the rat: a comparative study with heparin. Thromb Res 54:435–445

    Article  PubMed  CAS  Google Scholar 

  • Eriksson BI, Kalebo P, Ekman S, Lindbratt S, Kerry R, Close P (1994) Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 72:227–231

    PubMed  CAS  Google Scholar 

  • Eriksson BI, Ekman S, Kalebo P, Zachrisson B, Bach D, Close P (1996) Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393 Lancet 347:635–639

    CAS  Google Scholar 

  • Esmon NL, Owen WG, Esmon CT (1982)Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C.J Biol Chem 257:859–864

    CAS  Google Scholar 

  • Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin E et al (1993) Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemost 69:157–163

    PubMed  CAS  Google Scholar 

  • Fuchs J, Cannon CP (1995) Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. Circulation 92:727–733

    PubMed  CAS  Google Scholar 

  • Galdal KS, Lyberg T, Evensen SA, Nilsen E, Prydz H (1985) Thrombin induces thromboplastin synthesis in cultured vascular endothelial cells. Thromb Haemost 54:373–376

    PubMed  CAS  Google Scholar 

  • Ginsberg JS, Nurmohamed MT, Gent M, MacKinnon B, Sicurella J, Rill-Edwards P et al (1994) Use of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 90:2385–2389

    PubMed  CAS  Google Scholar 

  • Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators (1994) Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 90:1631–1637

    Google Scholar 

  • Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) lib Investigators (1996) A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 335:775–782

    Article  Google Scholar 

  • Gold HK, Torres FW, Garabedian HD, Werner W, Jang IK, Khan A et al (1993)Evidence for a rebound coagulation phenomenon after cessation of a 4-hour J Am Coll Cardiol 21:1039–1047

    CAS  Google Scholar 

  • Granger CB, Hirsch J, Califf RM, Col J, White HD, Betriu A et al (1996) Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 93:870–878

    PubMed  CAS  Google Scholar 

  • GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673–682

    Article  Google Scholar 

  • Harvey RP, Degryse E, Stefani L, Schamber F, Cazenave JP, Courtney M et al (1986) Cloning and expression of a cDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis. Proc Nat Acad Sci USA 83:1084–1088

    Article  CAS  Google Scholar 

  • Haskel EJ, Prager NA, Sobel BE, Abendschein DR (1991) Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 83:1048–1056

    PubMed  CAS  Google Scholar 

  • Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V (1989) Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation 79:657–665

    CAS  Google Scholar 

  • Hirsh J (1991) Heparin. N Engl J Med 324:1565–1574

    Article  PubMed  CAS  Google Scholar 

  • Hung DT, Vu TH, Nelken NA, Coughlin SR (1992) Thrombin-induced events in nonplatelet cells are mediated by the unique proteolytic mechanism established for the cloned platelet thrombin receptor. J Cell Biol 116:827–832

    Article  PubMed  CAS  Google Scholar 

  • Jurd KM, Stephens CJ, Black MM, Hunt BJ (1996) Endothelial cell activation in cutaneous vasculitis. Clin Exp Dermatol 21:28–32

    Article  PubMed  CAS  Google Scholar 

  • Kaiser B, Simon A, Markwardt F (1990) Antithrombotic effects of recombinant hirudin in experimental angioplasty and intravascular thrombolysis. Thromb Haemost 63:44–47

    PubMed  CAS  Google Scholar 

  • Kelton JG, Sheridan D, Brain H, Powers PJ, Turpie AG, Carter CJ (1984) Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia. J Lab Clin Med 103:606–612

    PubMed  CAS  Google Scholar 

  • Klement P, Borm A, Hirsh J, Maraganore J, Wilson G, Weitz J (1992) The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model. Thromb Haemost 68:64–68

    PubMed  CAS  Google Scholar 

  • Kottke-Marchant K, Zoldhelyi P, Zaramo C, Brooks L, Cianciolo C, Janssens S. (1996) The effect of desirudin vs. heparin on hemostatic parameters in acute coronary syndromes: the GUSTO lib hemostasis substudy. Circulation 94:1–742

    Google Scholar 

  • Lee LV (1995) Initial experience with hirudin and streptokinase in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 6 trial. Am J Cardiol 75:7–13

    Article  PubMed  CAS  Google Scholar 

  • Lefkovits J, Topol EJ (1994) Direct thrombin inhibitors in cardiovascular medicine. Circulation 90:1522–1536

    PubMed  CAS  Google Scholar 

  • Lewis BE, Ferguson JJ, Grassman ED, Fareed J, Walenga J, Joffrion JL et al (1996) Successful coronary interventions performed with argatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome. J Invasive Cardiol 8:410–417

    PubMed  Google Scholar 

  • Lidon RM, Theroux P, Juneau M, Adelman B, Maraganore J (1993) Initial experience with a direct antithrombin, hirulog, in unstable angina. Anticoagulant, antithrombotic, and clinical effects. Circulation 88:1495–1501

    CAS  Google Scholar 

  • Lidon RM, Theroux P, Lesperance J, Adelman B, Bonan R, Duval D et al (1994) A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 89:1567–1572

    PubMed  CAS  Google Scholar 

  • Lindahl U, Hook M (1978) Glycosaminoglycans and their binding to biological macromolecules. Annu Rev Biochem 47:385–417

    Article  PubMed  CAS  Google Scholar 

  • Longstaff C, Wong MY, Gaffney PJ (1993) An international collaborative study to investigate standardisation of hirudin potency. Thromb Haemost 69:430–435

    PubMed  CAS  Google Scholar 

  • Loscalzo J, Melnick B, Handin RI (1985) The interaction of platelet factor four and glycosaminoglycans. Arch Biochem Biophys 240:446–455

    Article  PubMed  CAS  Google Scholar 

  • Maraganore JM (1993) Pre-clinical and clinical studies on Hirulog: a potent and specific direct thrombin inhibitor. Adv Exp Med Biol 340:227–236

    PubMed  CAS  Google Scholar 

  • Markwardt F (1991) Past, present and future of hirudin. Haemostasis 21 [Suppl 1]:11–26

    PubMed  CAS  Google Scholar 

  • Matsuo T, Kario K, Chikahira Y, Nakao K, Yamada T (1992) Treatment of heparininduced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haematol 82:627–629

    Article  PubMed  CAS  Google Scholar 

  • Matthiasson SE, Lindblad B, Bergqvist D (1995) Prevention of experimental venous thrombosis in rabbits with different low molecular weight heparins, dermatan sulphate and hirudin. Haemostasis 25:124–132

    PubMed  CAS  Google Scholar 

  • Metz BK, Granger CB, White HD, Simes J, Topol EJ (1996) Streptokinase and hirudin reduces death and reinfarction in acute myocardial infarction compared with streptokinase and heparin: results from GUSTO-IIb. Circulation 94:1–430

    Google Scholar 

  • Narins CR, Hillegass WB Jr, Nelson CL, Tcheng JE, Harrington RA, Phillips HR et al (1996) Relation between activated clotting time during angioplasty and abrupt closure. Circulation 93:667–671

    PubMed  CAS  Google Scholar 

  • Neuhaus KL, von Essen R, Tebbe U, Jessel A, Heinrichs H, Maurer W et al (1994) Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK). Circulation 90:1638–1642

    PubMed  CAS  Google Scholar 

  • Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ (1994) Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 89:1802–1809

    PubMed  CAS  Google Scholar 

  • Pearson JD (1993) The control of production and release of haemostatic factors in the endothelial cell. Baillieres Clin Haematol 6:629–651

    Article  PubMed  CAS  Google Scholar 

  • Pearson JD (1994) Endothelial cell function and thrombosis. Baillieres Clin Haematol 7:441–452

    Article  PubMed  CAS  Google Scholar 

  • Phillips DR (1974) Thrombin interaction with human platelets. Potentiation of thrombin- induced aggregation and release by inactivated thrombin. Thromb Diath Haemorrh 32:207–215

    PubMed  CAS  Google Scholar 

  • Rigel DF, Olson RW, Lappe RW (1993) Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis. Circ Res 72:1091–1102

    PubMed  CAS  Google Scholar 

  • Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC (1991) Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation 84:232–243

    PubMed  CAS  Google Scholar 

  • Scharf M, Engels J, Tripier D (1989) Primary structures of new ’iso-hirudins’. FEBS Lett 255:105–110

    Article  PubMed  CAS  Google Scholar 

  • Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Soria J, Soria C et al (1994) A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis. Thromb Haemost 71:558–562

    PubMed  CAS  Google Scholar 

  • Schiele F, Vuillemenot A, Kramarz P, Kieffer Y, Anguenot T, Bernard Y et al (1995) Use of recombinant hirudin as antithrombotic treatment in patients with heparininduced thrombocytopenia. Am J Hematol 50:20–25

    Article  PubMed  CAS  Google Scholar 

  • Schini VB, Hendrickson H, Heublein DM, Burnett JC Jr, Vanhoutte PM (1989) Thrombin enhances the release of endothelin from cultured porcine aortic endothelial cells. Eur J Pharmacol 165:333–334

    Article  PubMed  CAS  Google Scholar 

  • Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Laarman GJ et al (1995) A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. N Engl J Med 333:757–763

    Article  CAS  Google Scholar 

  • Sharma GV, Lapsley D, Vita JA, Sharma S, Coccio E, Adelman B et al (1993) Usefulness and tolerability of hirulog, a direct thrombin-inhibitor, in unstable angina pectoris. Am J Cardiol 72:1357–1360

    Article  PubMed  CAS  Google Scholar 

  • Simes RJ, Granger CB, Antmann EM, Califf RM, Braunwald E, Topol EJ (1996) Impact of hirudin versus heparin on mortality and (re)infarction in patients with acute coronary syndromes: a prospective meta-analysis of the GUSTO-IIb and TIMI 9b trials. Circulation 94:1–430

    Google Scholar 

  • Smith GF, Shuman RT, Craft TJ, Gifford DS, Kurz KD, Jones ND et al (1996) A family of arginal thrombin inhibitors related to efegatran. Semin Thromb Hemost 22:173–183

    Article  PubMed  CAS  Google Scholar 

  • Stubbs MT, Bode W (1993) A player of many parts: the spotlight falls on thrombin’s structure. Thromb Res 69:1–58

    Article  PubMed  CAS  Google Scholar 

  • Tabata H, Mizuno K, Miyamoto A, Etsuda H, Isojima K, Satomura K et al (1992) The effect of a new thrombin inhibitor (argatroban) in the prevention of reocclusion after reperfusion therapy in patients with acute myocardial infarction. Circulation 86:1–260

    Google Scholar 

  • Talbot MD, Ambler J, Butler KD, Findlay VS, Mitchell KA, Peters RF et al (1989) Recombinant desulphatohirudin (CGP 39393) anticoagulant and antithrombotic properties in vivo. Thromb Haemost 61:77–80

    PubMed  CAS  Google Scholar 

  • Theroux P, Lidon R-M (1994) Anticougulants and their use in acute ischemic syndromes. In: Topol EJ (ed) Textbook of interventional cardiology, vol 1. Saunders, Philadelphia, pp 23–45

    Google Scholar 

  • Theroux P, Perez-Villa F, Waters D, Lesperance J, Shabani F, Bonan R (1995) Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 91:2132–2139

    PubMed  CAS  Google Scholar 

  • Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M et al (1993) Use of a direct antithrombin, Hirulog, in place of heparin during coronary angioplasty. Circulation 87:1622–1629

    CAS  Google Scholar 

  • Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ et al (1994) Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. Circulation 89:1557–1566

    CAS  Google Scholar 

  • van den Bos AA, Deckers JW, Heyndrickx GR, Laarman GJ, Suryapranata H, Zijlstra F et al (1993) Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 88:2058–2066

    PubMed  Google Scholar 

  • Vu TK, Wheaton VI, Hung DT, Charo I, Coughlin SR (1991) Domains specifying thrombin-receptor interaction. Nature 353:674–677

    Article  PubMed  CAS  Google Scholar 

  • Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J (1990) Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin Ill-independent inhibitors. J Clin Invest 86:385–391

    Article  PubMed  CAS  Google Scholar 

  • Zeymer U, von Essen R, Tebbe U, Michels HR, Jessel A, Vogt A et al (1995) Recombinant hirudin and front-loaded alteplase in acute myocardial infarction: final results of a pilot study. HIT-I (Hirudin for the Improvement of Thrombolysis). Eur Heart J 16 Suppl D:22–27

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. A. Lauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. M. Lincoff
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Drug Development, Parke-Davis Pharmaceutical Research Division, Warner-lambert Company, 2800 Plymouth Road, Ann Arbor, MI, 48105, USA

    Andrew C. G. Uprichard M.D. (Vice President) (Vice President)

  2. Vascular and Cardiac Diseases, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, MI, 48105, USA

    Kim P. Gallagher Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lauer, M.A., Lincoff, A.M. (1999). Parenteral Direct Antithrombins. In: Uprichard, A.C.G., Gallagher, K.P. (eds) Antithrombotics. Handbook of Experimental Pharmacology, vol 132. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59942-2_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-59942-2_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64190-9

  • Online ISBN: 978-3-642-59942-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation